ArticleInternational journal of nanomedicine2015
Compound antimalarial ethosomal cataplasm: preparation, evaluation, and mechanism of penetration enhancement.
Article in International journal of nanomedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 54 citations in OpenAlex.
- Untargeted UHPLC-Q-Exactive Orbitrap MS and Targeted UHPLC-QqQ-MS/MS for Exploring the Effective Components of "Wen Tong Plaster" Cataplasm in Treating Rats With Primary Dysmenorrhea.Journal of separation science · 2026Article
- Structural characterization of emulsion-type cataplasms with cross-linked networks and systematic establishment of structural parameters.Acta pharmaceutica Sinica. B · 2026Article
- Nanoformulation-Based Transdermal Drug Delivery: A Paradigm Shift in Antiparasitic Therapy for Zoonotic Diseases.Pharmaceutics · 2025Review
- Recent Advancement in Drug Development for Treating Malaria using Herbal Medicine and Nanotechnological Approach.Current pharmaceutical design · 2025Review
- Development and Characterization of a Hydrogel Containing Chloramphenicol-Loaded Binary Ethosomes for Effective Transdermal Permeation and Treatment Acne in Rat Model.International journal of nanomedicine · 2025Article
- Topical Delivery of Ketorolac Tromethamine via Cataplasm for Inflammatory Pain Therapy.Pharmaceutics · 2023Article
- Current advances in nanodrug delivery systems for malaria prevention and treatment.Discover nano · 2023Review
- Pioneer Use of Antimalarial Transdermal Combination Therapy in Rodent Malaria Model.Pathogens (Basel, Switzerland) · 2023Article
- Development of artesunate intelligent prodrug liposomes based on mitochondrial targeting strategy.Journal of nanobiotechnology · 2022Article
- Phospholipid Vesicles for Dermal/Transdermal and Nasal Administration of Active Molecules: The Effect of Surfactants and Alcohols on the Fluidity of Their Lipid Bilayers and Penetration Enhancement Properties.Molecules (Basel, Switzerland) · 2020Review
- Rheological and Mechanical Analyses of Felbinac Cataplasms by Using Box⁻Behnken Design.Pharmaceutics · 2018Article
- Antimalarial activity and metabolism of dihydroartemisinin-derived dimer.Parasitology research · 2018Article
- Development of triptolide-nanoemulsion gels for percutaneous administration: physicochemical, transport, pharmacokinetic and pharmacodynamic characteristics.Journal of nanobiotechnology · 2017Article
- Nanoparticle Delivery of Artesunate Enhances the Anti-tumor Efficiency by Activating Mitochondria-Mediated Cell Apoptosis.Nanoscale research letters · 2017Article
- Design of Drug Delivery Systems Containing Artemisinin and Its Derivatives.Molecules (Basel, Switzerland) · 2017Review
- Ethosomal nanocarriers: the impact of constituents and formulation techniques on ethosomal properties, in vivo studies, and clinical trials.International journal of nanomedicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malaria is still a serious public health problem in some parts of the world. The problems of recurrence and drug resistance are increasingly more serious. Thus, it is necessary to develop a novel antimalarial agent. The objectives of this study were to construct a novel compound antimalarial transdermal nanosystem-ethosomal cataplasm, to investigate its characteristics and efficiency, and to systematically explore the penetration-enhancing mechanisms of ethosomal cataplasm. Artesunate-loaded ethosomes and febrifugine-loaded ethosomes were prepared, and their characteristics were evaluated. Drug-loaded ethosomes were incorporated in the matrix of cataplasm to form the compound antimalarial ethosomal cataplasm. With the help of ethosomal technology, the accumulated permeation quantity of artesunate significantly increased at 8 hours after administration, which was 1.57 times as much as that of conventional cataplasm. Soon after administration, the ethosomal cataplasm could make a large quantity of antimalarial drug quickly penetrate through skin, then the remaining drug in the ethosomal cataplasm could be steadily released. These characteristics of ethosomal cataplasm are favorable for antimalarial drugs to kill Plasmodium spp. quickly and prevent the resurgence of Plasmodium spp. As expected, the ethosomal cataplasm showed good antimalarial efficiency in this experiment. The negative conversion rates were 100% and the recurrence rates were 0% at all dosages. The mechanism of penetration enhancement of the ethosomal cataplasm was systematically explored using an optics microscope, polarization microscope, and transmission electron microscopy. The microstructure, ultrastructure, and birefringent structure in skin were observed. Data obtained in this study showed that the application of ethosomal technology to antimalarial cataplasm could improve the transdermal delivery of drug, enhance the efficacy, and facilitate practical application in clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.